Helicobacter pylori infection
Conditions
Interventions
Intervention group (probiotics + quadruple therapy):Probiotic intervention group + Standard bismuth quadruple therapy
Placebo group:Oral placebo for 6 weeks + Standard bismuth quadruple therapy
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Age is 18-60 years old, gender is not limited; (2) Permanent residents who have lived in the local area for more than half a year; (3) Hp infection (positive 13C or 14C urea breath test); (4) Patients with upper gastrointestinal symptoms, such as: abdominal pain, bloating, belching, acid reflux, heartburn, etc.; (5) have not previously received HP eradication therapy; (6) During the trial, participants agree not to take any drugs, supplements, or other dairy products, including yogurt drinks; Willing to comply with all test requirements and procedures; Willing to participate in other interventional clinical studies during the trial period; Be able to fully understand the nature, purpose, benefits, and possible risks and side effects of this study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those who have a history of allergy to any drug in this study; (2) Have recently (within 4 weeks) taken H2receptor antagonist (H2RA), Proton pump inhibitor (PPI) and other drugs used in eradication programs; (3) previous history of long-term use of nonsteroidal anti-inflammatory drugs; (4) Severe heart and lung diseases, and liver and kidney insufficiency; (5) Patients with malignant tumors; (6) Those with a history of upper gastrointestinal surgery; (7) pregnant or lactating women; (8) Those with poor compliance and unable to cooperate with the clinical research; (9) Patients who are participating in other clinical trials; Those who do not meet the inclusion criteria, do not eat in accordance with the regulations, and the incomplete information affects the judgment of the effect.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of adverse effect;Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the intestinal flora;Serum C-reactive protein levels;Procalcitonin level;Liver function;Kidney function; | — |
Countries
China
Contacts
Public ContactWu Peiying
Shanghai General Hospital
Outcome results
None listed